Literature DB >> 9778756

Respiratory syncytial virus infection in older persons.

A R Falsey1.   

Abstract

Respiratory Syncytial Virus (RSV) is an increasingly recognized cause of serious disease in older adults. RSV causes excess morbidity and mortality in older persons residing in nursing homes and in the community. The study of RSV in adults has been hampered by the lack of sensitive methods for the diagnosis of acute infections. Such tools are needed to better understand the epidemiology and immunology of RSV in adults. The immune status of older adults has begun to be explored and preliminary data indicates that low serum neutralizing antibody may predispose to symptomatic RSV infection and that a greater diversity of antibody titres may be seen in the elderly compared to young adults. PFP-2, a candidate RSV subunit vaccine, has been evaluated in healthy and institutionalized elderly and been found to be safe and immunogenic.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778756     DOI: 10.1016/s0264-410x(98)00142-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

2.  Human respiratory syncytial virus glycoproteins are not required for apical targeting and release from polarized epithelial cells.

Authors:  Melissa Batonick; Antonius G P Oomens; Gail W Wertz
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

3.  Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract.

Authors:  Peter F Wright; Mine R Ikizler; Ricardo A Gonzales; Kecia N Carroll; Joyce E Johnson; Jay A Werkhaven
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes.

Authors:  Amit Agrawal; Ralph A Tripp; Larry J Anderson; Shuming Nie
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 5.  Paramyxovirus assembly and budding: building particles that transmit infections.

Authors:  Megan S Harrison; Takemasa Sakaguchi; Anthony P Schmitt
Journal:  Int J Biochem Cell Biol       Date:  2010-04-14       Impact factor: 5.085

6.  Structures of respiratory syncytial virus nucleocapsid protein from two crystal forms: details of potential packing interactions in the native helical form.

Authors:  K El Omari; B Dhaliwal; J Ren; N G A Abrescia; M Lockyer; K L Powell; A R Hawkins; D K Stammers
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-09-24

7.  Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.

Authors:  Sujin Lee; Robert S Mittler; Martin L Moore
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

Review 8.  Current research on respiratory viral infections: Fourth International Symposium.

Authors:  Michael G Ison; John Mills; Peter Openshaw; Maria Zambon; Albert Osterhaus; Frederick Hayden
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

9.  The role of influenza, RSV and other common respiratory viruses in severe acute respiratory infections and influenza-like illness in a population with a high HIV sero-prevalence, South Africa 2012-2015.

Authors:  Marthi A Pretorius; Stefano Tempia; Sibongile Walaza; Adam L Cohen; Jocelyn Moyes; Ebrahim Variava; Halima Dawood; Mpho Seleka; Orienka Hellferscee; Florette Treurnicht; Cheryl Cohen; Marietjie Venter
Journal:  J Clin Virol       Date:  2015-12-19       Impact factor: 3.168

Review 10.  Low zinc status: a new risk factor for pneumonia in the elderly?

Authors:  Junaidah B Barnett; Davidson H Hamer; Simin N Meydani
Journal:  Nutr Rev       Date:  2010-01       Impact factor: 7.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.